Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00095550 | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension | PHASE3 | COMPLETED | 496 | — | — | Oct 1, 2004 | Jun 1, 2005 | Apr 15, 2011 | 128 | United States, Canada +3 |
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | ACTIVE_COMPARATOR | - |
| A3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Irbesartan/HCTZ | DRUG | Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks. |
| Irbesartan monotherapy | DRUG | Tablets, Oral, 150 mg, Once daily, 12 weeks. |
| HCTZ monotherapy | DRUG | Tablets, Oral, 12.5 mg, Once daily, 12 weeks. |
Inclusion Criteria: * Willing to provide written informed consent * Subjects must have uncontrolled hypertension defined as: * average systolic blood pressure between 160 mmHg and 180 mmHg (while diastolic blood pressure is less than 110 mmHg) or * average diastolic blood pressure between 100 ...